Quark Pharmaceuticals

Quark Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of RNAi therapies. The main product lines include: QPI-1002, for delayed graft function (DGF) after kidney transplantation; QPI-1007, for non-arteritic anterior ischemic optic neuropathy (NAION).